Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2234-2243

  Modiano, Jaime F ^a,b,c,d,e,f   Bellgrau, Donald ^a,d,e,f   Cutter, Gary R ^g   Lana, Susan E ^h   Ehrhart, Nicole P ^h   Ehrhart, Ej ^h   Wilke, Vicki L ^b   Charles, J Brad ^h   Munson, Sibyl ^a   Scott, Milcah C ^b   Pozniak, John ^b   Carlson, Cathy S ^b,c   Schaack, Jerome ^d,f   Duke, Richard C ^a,d,f  

^a ApopLogic Pharmaceuticals   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CREATINE KINASE; CREATININE; FAS ANTIGEN; FAS LIGAND; POTASSIUM; SODIUM;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE NECROSIS; CANCER CELL DESTRUCTION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL DOG; HYPOTENSION; INFLAMMATION; LETHARGY; LYMPHOCYTIC INFILTRATION; NEUTROPHIL; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; MAMMALIA; RODENTIA;

EID: 84870618490     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.149     Document Type: Article

References (39)

1. Duke, RC, Ojcius, DM and Young, JD (1996). Cell suicide in health and disease. Sci Am 275: 80-87.
2. Modiano, JF, Sun, J, Lang, J, Vacano, G, Patterson, D, Chan, D et al. (2004). Fas liganddependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol 112: 54-65.
3. Zhang, HG, Bilbao, G, Zhou, T, Contreras, JL, Gómez-Navarro, J, Feng, M et al. (1998). Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol 72: 2483-2490.
4. Ogasawara, J, Watanabe-Fukunaga, R, Adachi, M, Matsuzawa, A, Kasugai, T, Kitamura, Y et al. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
5. Koshkina, NV, Khanna, C, Mendoza, A, Guan, H, DeLauter, L and Kleinerman, ES (2007). Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5: 991-999.
6. Worth, LL, Lafleur, EA, Jia, SF and Kleinerman, ES (2002). Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9: 823-827.
7. Gordon, N, Arndt, CA, Hawkins, DS, Doherty, DK, Inwards, CY, Munsell, MF et al. (2005). Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27: 611-615.
8. Chen, L, Park, SM, Tumanov, AV, Hau, A, Sawada, K, Feig, C et al. (2010). CD95 promotes tumour growth. Nature 465: 492-496.
9. Restifo, NP (2000). Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6: 493-495.
10. Modiano JF, Lamerato-Kozicki AR, Jubala CM, Coffey D, Borakove M, Schaack J et al. (2004). Fas ligand gene transfer for cancer therapy. Cancer Ther 2: 561-570.
11. O'Connell, J, Houston, A, Bennett, MW, O'Sullivan, GC and Shanahan, F (2001). Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7: 271-274.
12. Hohlbaum, AM, Saff, RR and Marshak-Rothstein, A (2002). Fas-ligand-iron fist or Achilles' heel? Clin Immunol 103: 1-6.
13. Leon, RP, Hedlund, T, Meech, SJ, Li, S, Schaack, J, Hunger, SP et al. (1998). Adenoviralmediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 95: 13159-13164.
14. Arai, H, Gordon, D, Nabel, EG and Nabel, GJ (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94: 13862-13867.
15. Loeffler, M, Le'Negrate, G, Krajewska, M and Reed, JC (2008). Inhibition of tumor growth using salmonella expressing Fas ligand. J Natl Cancer Inst 100: 1113-1116.
16. Ho, MY, Sun, GH, Leu, SJ, Ka, SM, Tang, SJ and Sun, KH (2008). Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer 123: 123-133.
17. Jubala, CM, Lamerato-Kozicki, AR, Borakove, M, Lang, J, Gardner, LA, Coffey, D et al. (2009). MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunol Immunother 58: 171-185.
18. Shimizu, M, Fontana, A, Takeda, Y, Yagita, H, Yoshimoto, T and Matsuzawa, A (1999). Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol 162: 7350-7357.
19. Hohlbaum, AM, Gregory, MS, Ju, ST and Marshak-Rothstein, A (2001). Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 167: 6217-6224.
20. Wada, A, Tada, Y, Kawamura, K, Takiguchi, Y, Tatsumi, K, Kuriyama, T et al. (2007). The effects of FasL on inflammation and tumor survival are dependent on its expression levels. Cancer Gene Ther 14: 262-267.
21. Shudo, K, Kinoshita, K, Imamura, R, Fan, H, Hasumoto, K, Tanaka, M et al. (2001). The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 31: 2504-2511.
22. Gregory, MS, Repp, AC, Holhbaum, AM, Saff, RR, Marshak-Rothstein, A and Ksander, BR (2002). Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol 169: 2727-2735.
23. Simon, AK, Gallimore, A, Jones, E, Sawitzki, B, Cerundolo, V and Screaton, GR (2002). Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2: 315-322.
24. Paoloni, M and Khanna, C (2008). Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
25. Bianco, SR, Sun, J, Fosmire, SP, Hance, K, Padilla, ML, Ritt, MG et al. (2003). Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 10: 726-736.
26. Vail, DM (2004). Veterinary Co-operative Oncology Group. Vet Comp Oncol 2: 194.
27. Kleinerman, ES, Maeda, M and Jaffe, N (1993). Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 62: 101-107.
28. Powers, BE, Withrow, SJ, Thrall, DE, Straw, RC, LaRue, SM, Page, RL et al. (1991). Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67: 126-134.
29. Modiano JF, Breen M, Lana SE, Ehrhart N, Fosmire SP, Thomas R et al. (2006). Naturally occurring translational models for development of cancer therapy. Gene Ther Mol Biol 10: 31-40.
30. Scott, MC, Sarver, AL, Gavin, KJ, Thayanithy, V, Getzy, DM, Newman, RA et al. (2011). Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 49: 356-367.
31. Andrawiss, M, Opolon, P, Benihoud, K, Devauchelle, P, Di Falco, N, Villette, JM et al. (1999). Adenovirus-mediated gene transfer in dog prostate: a preclinical study of a relevant model system for gene therapy of human prostatic cancer. Prostate Cancer Prostatic Dis 2: 25-35.
32. Zachos, TA, Aiken, SW, DiResta, GR and Healey, JH (2001). Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors. Clin Orthop Relat Res < Volume>: 230-236.
33. Regardsoe, EL, McMenamin, MM, Charlton, HM and Wood, MJ (2004). Local adenoviral expression of Fas ligand upregulates pro-inflammatory immune responses in the CNS. Gene Ther 11: 1462-1474.
34. Ehrhart, N, Dernell, WS, Hoffmann, WE, Weigel, RM, Powers, BE and Withrow, SJ (1998). Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 213: 1002-1006.
35. Phillips, B, Powers, BE, Dernell, WS, Straw, RC, Khanna, C, Hogge, GS et al. (2009). Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 45: 33-38.
36. Thomas, R, Scott, A, Langford, CF, Fosmire, SP, Jubala, CM, Lorentzen, TD et al. (2005). Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res 15: 1831-1837.
37. Thomas, R, Wang, HJ, Tsai, PC, Langford, CF, Fosmire, SP, Jubala, CM et al. (2009). Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Res 17: 365-377.
38. Tamburini, BA, Trapp, S, Phang, TL, Schappa, JT, Hunter, LE and Modiano, JF (2009). Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS ONE 4: e5549.
39. Livak, KJ and Schmittgen, TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.